Newsfeeds - Spark Newswire

1 minute read

Corcept Therapeutics Stock Drops After Disappointing Interim Data From Relacorilant Plus Nab-Paclitaxel Trial In Pancreatic Cancer

Today, 2:22 AM

Corcept Therapeutics Incorporated (NASDAQ:CORT) has announced preliminary results from its Phase 3 RELIANT trial of relacorilant for metastatic pancreatic cancer. The…

CORT

2 minute read

Corcept Therapeutics Stops Enrollment In RELIANT Trial; Says ‘the apparent level of benefit does not justify its further study as a treatment for end-stage pancreatic cancer’

By Bill Haddad

Today, 2:22 AM

Enrollment stopped in RELIANT trial Antitumor activity observed in heavily pretreated patients with metastatic pancreatic cancer, including those previously treated with nab-paclitaxel; addition of relacorilant to

CORT

32 minute read

Uncategorized

Earnings Scheduled For May 6, 2021

By Benzinga Insights

Today, 2:22 AM

Companies Reporting Before The Bell • ViacomCBS (NASDAQ:VIAC) is projected to report quarterly earnings at $1.22 per share on revenue of $7.30 billion.

AAOI